Natural products (target to lead II) 01

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/20

encourage image

There's no tags or description

Looks like no tags are added yet.

21 Terms

1
New cards

Natural products

- Compounds obtained from living organisms: plants, animals

- Can provide biolo active compounds & starting pts for drug discovery

<p>- Compounds obtained from living organisms: plants, animals</p><p>- Can provide biolo active compounds & starting pts for drug discovery</p>
2
New cards

Secondary (specialized) metabolites

- Compounds indirectly involved in core growth & reprod

- Help organisms interact w their enviro: defense, comp, signaling

- Biolo active โ†’ source of drug leads

3
New cards

Searching for natural products

1. Get samples from a biolo source: plant, etc.

2. Prep extracts & screen for biolo activity

3. Isolate & purify active compounds

4. Determine chem structure

5. Confirm biolo activity

1a Biolo or trad knowledge can guide search

4
New cards

Challenges of natural prods as leads

- Active compounds can occur in v small amounts

- Hard to isolate & purify

- Chemically complex structures

- Challenging synth & mod

- Issues w supply & sustainable prod (ex: spongistatin)

5
New cards

Natural products must be scalable

- Drug development needs large & reliable supplies

- Production must be scalable, reproducible, econo practical, sustainable

- Possible approaches: fermentation, cultivation

6
New cards

Spongistatin (supply limits development)

  • Spongistatin 1 isolated from marine sponges

  • Very potent antitumor activity

  • Very low natural abundance โ†’ major supply challenge

  • Requires an alternative, scalable source for further development


<ul><li><p>Spongistatin 1 isolated from marine sponges </p></li><li><p>Very potent antitumor activity </p></li><li><p>Very low natural abundance โ†’ major supply challenge</p></li><li><p>Requires an alternative, scalable source for further development</p></li></ul><p></p>
7
New cards

Rational drug design

  • Uses existing knowledge to design active molecules

  • Design or modify structures to improve desired properties

  • Info from enzyme substrates, natural inhibitors, etc.

  • Ex: captopril, acyclovir


<ul><li><p>Uses existing knowledge to design active molecules</p></li><li><p>Design or modify structures to improve desired properties</p></li><li><p>Info from enzyme substrates, natural inhibitors, etc.</p></li><li><p>Ex: captopril, acyclovir</p></li></ul><p></p>
8
New cards

Combinatorial chemistry (CC)

- Labo technique that rapidly creates & evaluates related compound libraries

- Systematically synth's combo's of diff chem building blocks

- Compounds may be prod & screened to identify promising hits

- Ex: Sorafenib (Nexavar)

9
New cards

Combinatorial search

1. Start w a common chem scaffold

2. Attach diff building blocks at diff positions

3. Generate a library of related compounds

4. Screen compounds individually or in mixtures (pools)

5. Active pool โ†’ deconvolution

6. Identify active compound(s)

10
New cards

Sorafenib (Nexavar) - Combinatorial chemistry

  • Developed initially as a RAF kinase inhibitor

  • CC used to explore related compounds & identify an alt. core/scaffold

  • Promising compounds underwent further optimization

  • Ultimately developed into sorafenib, a multikinase inhibitor


<ul><li><p>Developed initially as a RAF kinase inhibitor </p></li><li><p>CC used to explore related compounds &amp; identify an alt. core/scaffold </p></li><li><p>Promising compounds underwent further optimization </p></li><li><p>Ultimately developed into sorafenib, a multikinase inhibitor</p></li></ul><p></p>
11
New cards

Structure-based De Novo drug design

- Computer-assisted generation of new molecular structures

- Uses 3D structure of a biolo target

- Designs molecules to complement a binding site/pocket

- Target structures can come from x-ray crystallography, etc.

12
New cards

Process for structure-based De Novo drug design

1. 3D structure of biolo target

2. Identify active site

3. Analyze shape & chem int's

4. Computationally gen. candidate molecules

5. Dock & score predicted int's

6. Synth & exp. test promising compounds

13
New cards

What makes a useful lead?

- Confirmed biolo activity

- Some selectivity for desired target/effect

- Practical to synth

14
New cards

Structure-activity relationships (SAR) vs.

Structure-property relationships (SPR)

- SAR: How structural changes affect biolo activity

- SPR: How structural changes affect physicochem/drug-like properties

- Optimize multiple properties simultaneously: potency, selectivity, etc.

15
New cards

SAR process

1. Design structural mod's to the lead

2. Synth new analogues

3. Test biolo activity

4. Compare structure & activity

5. Identify features important for activity

6. Design next compounds using results

7. Repeat to improve lead (new lead)

<p>1. Design structural mod's to the lead</p><p>2. Synth new analogues</p><p>3. Test biolo activity</p><p>4. Compare structure &amp; activity</p><p>5. Identify features important for activity</p><p>6. Design next compounds using results</p><p>7. Repeat to improve lead (new lead)</p>
16
New cards

SPR process

1. Lead โ†’ molecule synth'd โ†’ compound

2. Various tests performed (properties)

3. Compare structure & activity

4. Results help determine SPR

5. Important property or structural feature discovered โ†’ New lead

<p>1. Lead โ†’ molecule synth'd โ†’ compound</p><p>2. Various tests performed (properties)</p><p>3. Compare structure &amp; activity</p><p>4. Results help determine SPR</p><p>5. Important property or structural feature discovered โ†’ New lead</p>
17
New cards

Potency (SPR)

- Dose thats prods biolo actiivty

- Aim for lowest dose possible (low dose = high potency)

18
New cards

Selectivity (SPR)

- Selectivity ratio = concen for undesired activity รท concen for desired activity

- Greater selectivity = higher concen needed for undesired activity relative to desired activity

<p>- Selectivity ratio = concen for undesired activity รท concen for desired activity</p><p>- Greater selectivity = higher concen needed for undesired activity relative to desired activity</p>
19
New cards

Drug-like properties

- Strong in vitro activity not enough

- Compound must reach action site at sufficient concen.

- Evaluate & optimize drug-like properties: solubility & permeability

- Computational methods to predict & prioritize compounds

20
New cards

Drug candidate

- Selected after lead optimization + for further development

- Practical synth & developmental pathway

- Backup compounds can be retained

21
New cards

Drug candidates have a well-characterized...

- Chem structure & properties

- BIolo activity

- Drug-like / ADME properties

- Prelim. safety profile